High glucose variability is associated with poor neurodevelopmental outcomes in neonatal hypoxic ischemic encephalopathy

J Neonatal Perinatal Med. 2015;8(2):119-24. doi: 10.3233/NPM-15814107.

Abstract

Background: In neonatal hypoxic ischemic encephalopathy (HIE), hypo- and hyperglycemia have been associated with poor outcomes. However, glucose variability has not been reported in this population.

Objective: To examine the association between serum glucose variability within the first 24 hours and two-year neurodevelopmental outcomes in neonates cooled for HIE.

Study design: In this retrospective cohort study, glucose, clinical and demographic data were documented from 23 term newborns treated with whole body therapeutic hypothermia. Severe neurodevelopmental outcomes from planned two-year assessments were defined as the presence of any one of the following: Gross Motor Function Classification System levels 3 to 5, Bayley III Motor Standard Score <70, Bayley III Language Score <70 and Bayley III Cognitive Standard Score <70.

Results: The neurodevelopmental outcomes from 8 of 23 patients were considered severe, and this group demonstrated a significant increase of mean absolute glucose (MAG) change (-0.28 to -0.03, 95% CI, p = 0.032). There were no significant differences between outcome groups with regards to number of patients with hyperglycemic means, one or multiple hypo- or hyperglycemic measurement(s). There were also no differences between both groups with mean glucose, although mean glucose standard deviation was approaching significance.

Conclusions: Poor neurodevelopmental outcomes in whole body cooled HIE neonates are significantly associated with MAG changes. This information may be relevant for prognostication and potential management strategies.

Keywords: Neonatal; glucose; hypothermia; hypoxic ischemic encephalopathy; treatment outcomes.

MeSH terms

  • Biomarkers / blood
  • Canada / epidemiology
  • Critical Care*
  • Glycated Hemoglobin / metabolism
  • Glycemic Index
  • Humans
  • Hyperglycemia / complications
  • Hyperglycemia / mortality
  • Hyperglycemia / physiopathology*
  • Hypoglycemia / complications
  • Hypoglycemia / mortality
  • Hypoglycemia / physiopathology*
  • Hypothermia, Induced / methods*
  • Hypoxia-Ischemia, Brain / blood
  • Hypoxia-Ischemia, Brain / complications
  • Hypoxia-Ischemia, Brain / physiopathology*
  • Hypoxia-Ischemia, Brain / therapy
  • Infant, Newborn
  • Monitoring, Physiologic
  • Neurodevelopmental Disorders / blood
  • Neurodevelopmental Disorders / etiology
  • Neurodevelopmental Disorders / physiopathology*
  • Neurodevelopmental Disorders / prevention & control
  • Retrospective Studies

Substances

  • Biomarkers
  • Glycated Hemoglobin A
  • hemoglobin A1c protein, human